Meta-analysis of 18 trials (1823 adults with myasthenia gravis): treatment beat control on QMG (MD −2.40) and MG-ADL (MD −1.59). Older mean trial age was associated with smaller QMG benefit (β 1.21 per 10 years; p=0.047), most for FcRn inhibitors, but not MG-ADL.
Meta-analysisn = 1,823
Nelke et al. Age and Treatment Efficacy in Myasthenia Gravis: A Systematic Review, Meta-Analysis, and Meta-Regression